Leonard Egede explains why PHQ-9 screening belongs in every cardio-kidney-metabolic (CKM) syndrome risk assessment—and how community pharmacists can reach patients the formal system misses.
Leonard E. Egede, MD, MS, FACP
Advertisement
Leonard E. Egede, MD, MS, FACP, is chair of the Department of Medicine at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences.
Articles by Leonard E. Egede, MD, MS, FACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Outcomes of Older Patients on Enfortumab Vedotin for Urothelial Carcinoma
2
FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence
3
Are Non-Opioid Therapies Finally Challenging Opioids in Acute Pain Management?
4
Single-Center Experience With Vorasidenib in Patients With Grade 3 or 4 IDH-Mutant Gliomas
5